CN114651063A - 用于表达重组治疗性肽的n-末端延伸序列 - Google Patents

用于表达重组治疗性肽的n-末端延伸序列 Download PDF

Info

Publication number
CN114651063A
CN114651063A CN202080077076.8A CN202080077076A CN114651063A CN 114651063 A CN114651063 A CN 114651063A CN 202080077076 A CN202080077076 A CN 202080077076A CN 114651063 A CN114651063 A CN 114651063A
Authority
CN
China
Prior art keywords
seq
gene sequence
modified gene
vector
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080077076.8A
Other languages
English (en)
Chinese (zh)
Inventor
拉梅什·维恩凯特·马图尔
拉然·西拉曼
帕万·雷迪·雷加蒂
纳伦德尔·大卫·曼特纳
马希马·达特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biological E Ltd
Original Assignee
Biological E Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological E Ltd filed Critical Biological E Ltd
Publication of CN114651063A publication Critical patent/CN114651063A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202080077076.8A 2019-09-13 2020-09-12 用于表达重组治疗性肽的n-末端延伸序列 Pending CN114651063A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201941009728 2019-09-13
IN201941009728 2019-09-13
PCT/IN2020/050790 WO2021048878A1 (en) 2019-09-13 2020-09-12 N-terminal extension sequence for expression of recombinant therapeutic peptides

Publications (1)

Publication Number Publication Date
CN114651063A true CN114651063A (zh) 2022-06-21

Family

ID=74866188

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080077076.8A Pending CN114651063A (zh) 2019-09-13 2020-09-12 用于表达重组治疗性肽的n-末端延伸序列

Country Status (14)

Country Link
US (1) US20230002468A1 (ko)
EP (1) EP4028519A4 (ko)
JP (1) JP2022548598A (ko)
KR (1) KR20220058631A (ko)
CN (1) CN114651063A (ko)
AU (1) AU2020345138A1 (ko)
BR (1) BR112022004601A2 (ko)
CA (1) CA3150902A1 (ko)
CO (1) CO2022004535A2 (ko)
CU (1) CU20220017A7 (ko)
IL (1) IL291127A (ko)
MX (1) MX2022003002A (ko)
WO (1) WO2021048878A1 (ko)
ZA (1) ZA202202579B (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4314034A2 (en) * 2021-03-31 2024-02-07 Biological E Limited Constructs and methods for increased expression of polypeptides

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272125A1 (en) * 2001-07-24 2005-12-08 Thomas Hoeg-Jensen Method for making acylated polypeptides
US20130330335A1 (en) * 2010-03-23 2013-12-12 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
CN104302408A (zh) * 2012-02-27 2015-01-21 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
CN107881187A (zh) * 2017-11-20 2018-04-06 珠海联邦制药股份有限公司 将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
CN108218997A (zh) * 2017-12-30 2018-06-29 北京中科唯新生物医学研究所有限公司 一种用于纯化蛋白的表达载体
WO2018136572A1 (en) * 2017-01-18 2018-07-26 Savior Lifetec Corporation Expression construct and method for producing proteins of interest
WO2019143193A1 (ko) * 2018-01-19 2019-07-25 주식회사 펩진 재조합 폴리펩타이드 생산용 n-말단 융합 파트너 및 이를 이용하여 재조합 폴리 펩타이드를 생산하는방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019082138A1 (en) * 2017-10-27 2019-05-02 Lorven Biologics Private Limited PROCESS FOR THE PREPARATION OF LIRAGLUTIDE USING RECOMBINANT SACCHAROMYCES CEREVISIAE

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272125A1 (en) * 2001-07-24 2005-12-08 Thomas Hoeg-Jensen Method for making acylated polypeptides
US20130330335A1 (en) * 2010-03-23 2013-12-12 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
CN104302408A (zh) * 2012-02-27 2015-01-21 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
WO2018136572A1 (en) * 2017-01-18 2018-07-26 Savior Lifetec Corporation Expression construct and method for producing proteins of interest
CN107881187A (zh) * 2017-11-20 2018-04-06 珠海联邦制药股份有限公司 将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
CN108218997A (zh) * 2017-12-30 2018-06-29 北京中科唯新生物医学研究所有限公司 一种用于纯化蛋白的表达载体
WO2019143193A1 (ko) * 2018-01-19 2019-07-25 주식회사 펩진 재조합 폴리펩타이드 생산용 n-말단 융합 파트너 및 이를 이용하여 재조합 폴리 펩타이드를 생산하는방법

Also Published As

Publication number Publication date
EP4028519A1 (en) 2022-07-20
US20230002468A1 (en) 2023-01-05
AU2020345138A1 (en) 2022-04-21
CA3150902A1 (en) 2021-03-18
KR20220058631A (ko) 2022-05-09
MX2022003002A (es) 2022-04-07
WO2021048878A1 (en) 2021-03-18
BR112022004601A2 (pt) 2022-05-31
IL291127A (en) 2022-05-01
EP4028519A4 (en) 2023-10-11
ZA202202579B (en) 2022-10-26
CU20220017A7 (es) 2022-10-11
CO2022004535A2 (es) 2022-04-29
JP2022548598A (ja) 2022-11-21

Similar Documents

Publication Publication Date Title
US20100167342A1 (en) Method of producing biologically active polypeptide having insulinotropic activity
KR100959549B1 (ko) 글루카곤 유사 펩타이드 1 glp-1(7-36)과 glp-1 유사체를 생산하는 방법
KR102495283B1 (ko) 재조합 숙주 세포에서 탄소 공급원 조절된 단백질 생산
CN110724187B (zh) 一种高效表达利拉鲁肽前体的重组工程菌及其应用
US10000544B2 (en) Process for production of insulin and insulin analogues
KR101026526B1 (ko) 대장균에서 외래단백질을 분비 생산하는 방법
CN117466990A (zh) 一种重组人源xvii型胶原蛋白及其制备方法与应用
WO2020258372A1 (zh) 硫氧还蛋白突变体、其制备方法及其在重组融合蛋白生产中的应用
CN114651063A (zh) 用于表达重组治疗性肽的n-末端延伸序列
JP7266325B2 (ja) 蛍光タンパク質フラグメントを含む融合タンパク質およびその用途
WO2005100388A1 (en) Production of insulinotropic peptides
AU2019218315A1 (en) Codon optimized precursor gene and signal peptide gene of human insulin analogue
CN114933658B (zh) 一种短肽元件及其应用方法
KR20230165291A (ko) 폴리펩티드의 발현 증가를 위한 구축물 및 방법
KR100368073B1 (ko) 융합파트너를 이용한 재조합 단백질의 제조방법
EP0381433B1 (en) A method for the production of glucagon
OA20681A (en) N-terminal extension sequence for expression of recombinant therapeutic peptides.
Yan et al. Overexpression of a small medicinal peptide from ginseng in the yeast Pichia pastoris
EA044776B1 (ru) Последовательность n-концевого удлинения для экспрессии рекомбинантных терапевтических пептидов
CN114686504A (zh) Lpp或其突变体作为分子伴侣在大肠杆菌中分泌表达重组蛋白的应用
WO2005068658A1 (en) Rapid screening method of translational fusion partners for producing recombinant proteins and translational fusion partners screened therefrom
US20230312668A1 (en) Insulin aspart derivative, and preparation method therefor and use thereof
US20200024321A1 (en) Expression and large-scale production of peptides
US10273520B2 (en) Means and methods for hyper-production of authentic human basic fibroblast growth factor in Escherichia coli
KR20200082618A (ko) 인슐린 과발현용 램프 태그 및 이를 이용한 인슐린의 제조방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination